Identifying why small cell lung cancer becomes resistant to chemotherapy
Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer
This study is looking into why small cell lung cancer often doesn't respond to chemotherapy, hoping to find new ways to treat it better for patients who are facing this tough disease.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10465193 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind chemotherapy resistance in small cell lung cancer (SCLC), a type of lung cancer with a very low survival rate. By analyzing genetic changes in tumor samples from patients who have relapsed after treatment, the study aims to uncover new therapeutic targets. Additionally, a novel mouse model that mimics human SCLC will be used to test potential treatments and understand how the cancer develops resistance. This approach could lead to more effective therapies for patients suffering from this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer who have experienced a relapse after initial chemotherapy treatment.
Not a fit: Patients with other types of lung cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that improve survival rates for patients with small cell lung cancer.
How similar studies have performed: Previous research has shown promise in identifying resistance mechanisms in other cancers, suggesting that this approach could yield valuable insights for small cell lung cancer as well.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Govindan, Ramaswamy — Washington University
- Study coordinator: Govindan, Ramaswamy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.